The Grim Reality Before Insulin: Diabetes as a Death Sentence

For millennia, a diagnosis of what we now call diabetes carried an unambiguous and rapidly approaching end. Ancient physicians from Egypt, India, and Greece described a mysterious wasting disease characterized by unquenchable thirst, excessive urination, and rapid emaciation. The Greek physician Aretaeus of Cappadocia coined the term diabetes, meaning “siphon,” to capture the relentless flow of fluid through the body. Treatment was limited to starvation diets, herbal concoctions, and opium, none of which could halt the inevitable decline. Children and young adults with acute-onset diabetes—today’s Type 1—rarely survived more than a few months or a couple of years, their bodies literally consuming themselves as they starved in the midst of plenty. The emotional and physical toll on families was devastating. The disease was an absolute mystery; doctors knew that sugar spilled into the urine, that the blood became thick with glucose, but the fundamental mechanism remained hidden within the small, lobulated organ nestled behind the stomach: the pancreas.

The Elusive Pancreatic Secret: Setting the Scientific Stage

The connection between the pancreas and diabetes was slowly unearthed through painstaking animal experimentation. In 1889, German physiologists Oskar Minkowski and Joseph von Mering removed the pancreas from a dog and famously noticed that the animal’s urine attracted swarms of flies. They tested the urine and found it loaded with sugar, establishing for the first time that the pancreas was essential for carbohydrate metabolism. However, the exact substance responsible remained a ghost. Researchers assumed that the pancreatic islets—clusters of cells described by Paul Langerhans in 1869—produced an internal secretion that regulated blood sugar. Yet every attempt to isolate this hypothetical hormone failed because the pancreas’s potent digestive enzymes destroyed the very substance scientists sought to extract.

The challenge was monumental. Scientists worldwide attempted to produce a pancreatic extract that could safely and consistently lower blood glucose. Names like Georg Zuelzer in Germany and E.L. Scott in the United States produced early, crude extracts that showed some promise, but their results were inconsistent and toxic. The scientific community grew deeply skeptical. Many prominent endocrinologists believed that the internal secretion could never be isolated in a usable form, that the pancreas’s dual function—exocrine and endocrine—created an insurmountable barrier. This was the state of exasperation and near-despair in the fall of 1920 when a young, relatively inexperienced surgeon with a bold idea entered the story.

The Toronto Breakthrough: Banting, Best, and the Summer of 1921

Frederick Banting was not a diabetes expert. He was a war veteran and orthopedic surgeon struggling to build a practice in London, Ontario. One sleepless night, after reading an article about a case of pancreatic duct obstruction, an idea crystallized. He scribbled a note: “Ligate pancreatic ducts of dogs. Wait six to eight weeks for degeneration. Remove the residue and extract.” The concept was elegantly simple: tie off the ducts of the pancreas to kill the enzyme-producing acinar cells, leaving the islets of Langerhans intact, and then extract the elusive internal secretion from the remaining tissue without the destructive interference of digestive ferments.

Banting took his idea to J.J.R. Macleod, a seasoned professor of physiology at the University of Toronto. Macleod was initially skeptical; the plan was not entirely original, and he knew of the many failures that preceded it. He eventually provided Banting with a modest laboratory and ten dogs for the summer, along with a medical student assistant, Charles Best. Macleod then departed for a holiday, leaving the two young men to their work.

The summer of 1921 was a crucible of relentless labor, failure, and sacrifice. Banting and Best performed meticulous surgery, tying off the pancreatic ducts. They struggled with infections, lost animals, and the persistent difficulty of finding the exact right method to grind, extract, and filter the degenerated tissue. Finally, on July 30, they injected their crude extract, which they called “isletin,” into a diabetic dog whose pancreas had been removed. The dog’s blood sugar fell dramatically. The animal, previously comatose, lifted its head, regained strength, and lived for several more hours. They had proven that a pancreatic extract free of digestive enzymes could reverse the deadly metabolic state. The experiment’s results, though crude, were a thunderstrike of clarity. The substance they later renamed insulin was real, and it worked.

Refining the Miracle: From Crude Extract to Clinical Reality

The proof-of-concept was staggering, but the extract was impure, variable in potency, and could not be produced in sufficient quantity for human use. A new phase began when Macleod returned and, convinced by the data, threw the full resources of his laboratory behind the project. A critical advancement came with the invitation of biochemist James Collip to the team. Collip’s genius lay in purification. He developed an alcohol-fractionation method that precipitated insulin in a far more concentrated and less toxic form, using the pancreas glands of fetal calves from the slaughterhouse, which naturally contained a higher proportion of islet tissue. Without Collip’s purification work, insulin would have remained a laboratory curiosity, too dangerous to administer repeatedly.

The first human test, on January 11, 1922, was a devastating setback. Leonard Thompson, a 14-year-old boy dying of diabetes in Toronto General Hospital, received a dose of the early extract. The injection caused a sterile abscess, and his blood sugar reduction was minimal. The team realized they were on the brink of failure. Collip worked with furious intensity for another twelve days, perfecting his purification protocol. On January 23, they tried again. The second injection was pure and potent. Thompson’s blood sugar fell from 520 mg/dL to 120 mg/dL, his ketones vanished from his urine, and his physical deterioration reversed. He gained weight and strength and walked out of the hospital, a literal resurrection. The news electrified the medical world. The death sentence was lifted.

The Nobel Prize, Controversy, and the Mass Production Challenge

The Nobel Prize in Physiology or Medicine was awarded in 1923 to Frederick Banting and J.J.R. Macleod, a decision that ignited deep resentment. Banting, furious that his partner Charles Best was omitted, shared his prize money with Best. Macleod, in turn, shared his with Collip. The recognition of only two individuals masked the essential collaborative nature of the discovery and the raw, emotional stakes each person had invested. Yet, despite the personal acrimony, the scientific achievement stood unassailable.

The immediate challenge was scaling production from a university lab to a global necessity. The University of Toronto signed a pioneering patent agreement with Eli Lilly and Company for one dollar, granting them manufacturing rights while retaining the university’s control over quality. This innovative model allowed pharmaceutical companies to bring insulin to the masses while preventing a single company from monopolizing the life-saving drug. Lilly’s scientists engineered methods to vastly increase output, and other manufacturers worldwide licensed the process. Within two years, insulin was available on every inhabited continent, transforming children’s hospital wards from places of certain death into centers of recovery. For the first time, patients were not just surviving; they were regaining their lives.

The Evolution of Insulin Formulations: A Century of Refinement

The original insulin, while a miracle, was limited. Its action was short and peaked sharply, requiring multiple daily injections and causing dangerous hypoglycemic swings. The next hundred years became a quest to mimic the body’s own intricate, basal-and-bolus rhythm of insulin secretion.

From Animal-Sourced to Biosynthetic Human Insulin

For over five decades, insulin extracted from the pancreases of pigs and cattle was the standard. Porcine insulin, differing from human insulin by a single amino acid, and bovine insulin, by three, saved millions of lives but occasionally caused allergic reactions, immune-mediated resistance, and lipoatrophy (the shrinking of fat tissue at injection sites). The monumental shift came in 1978 when Genentech, using recombinant DNA technology, produced the first biosynthetic human insulin in bacteria. Diabetes UK chronicles how this breakthrough eliminated animal-derived impurities and ushered in an era of unlimited, consistent supply. Today, genetically engineered human insulin and its more sophisticated analogues, produced in yeast or E. coli, are the global standard.

The Rise of Insulin Analogues: Precision Engineering

The development of insulin analogues through slight modifications of the amino acid sequence revolutionized blood sugar control. Rapid-acting analogues like insulin lispro, aspart, and glulisine have structural changes that prevent the hexamer formation that delays absorption. They can be injected immediately before meals, peaking in about an hour and clearing quickly, drastically reducing post-meal hyperglycemia and late-cycling hypoglycemia. Long-acting basal analogues, such as insulin glargine and detemir, form microprecipitates in the subcutaneous tissue or bind to albumin, providing a flat, peakless insulin release lasting up to 24 hours. The newest generation, ultra-long-acting analogues like insulin degludec (over 42 hours), offers patients unprecedented flexibility in the timing of their daily basal dose. These engineered therapies have transformed the concept of a “diabetic diet” into a more adaptable lifestyle.

Forms of Diabetes and the Therapeutic Role of Insulin

Insulin therapy is not a monolith; its role depends entirely on the underlying pathology. In Type 1 diabetes, an autoimmune attack destroys the pancreatic beta cells, rendering the body completely unable to produce insulin. For these individuals, exogenous insulin is not a treatment but absolute hormone replacement therapy, and survival depends on minute-to-minute management. Type 2 diabetes is a dual defect of progressive insulin resistance and declining insulin secretion. Initially managed with oral medications that improve insulin sensitivity or stimulate remaining beta cells, the disease inevitably exhausts the pancreas over time in many patients. Ultimately, insulin becomes a necessary and powerful tool to overcome resistance and protect vital organs from glucotoxicity. Insulin is also essential in gestational diabetes when dietary measures fail to protect both mother and fetus, and in other specific forms like pancreatic diabetes caused by surgery, pancreatitis, or cystic fibrosis.

The Architecture of a Modern Insulin Regimen: Pumps, Pens, and Closed-Loops

The tools of insulin delivery have evolved as dramatically as the hormone itself. The glass syringe and reusable needle have given way to discreet, prefilled insulin pens with micro-fine needles that reduce pain and dosing errors. For those seeking the most physiologic replacement, continuous subcutaneous insulin infusion (CSII) via an insulin pump provides a constant trickle of rapid-acting insulin as a customized basal rate, with precise boluses delivered at the touch of a button for meals and corrections. According to the National Institute of Diabetes and Digestive and Kidney Diseases, pump therapy can significantly reduce A1C levels and the frequency of severe hypoglycemia compared to multiple daily injections in motivated patients.

The apex of this evolution is the hybrid closed-loop system, often called an artificial pancreas. These systems integrate a continuous glucose monitor (CGM) with an insulin pump via a control algorithm that automatically adjusts basal insulin delivery based on real-time glucose readings, reducing the relentless cognitive burden on the user. The system predicts rises and falls and intervenes before the person even knows a problem is developing. While users still must announce meals, these systems have dramatically improved time-in-range outcomes and sleep quality, representing the most significant advancement since the discovery of insulin itself.

Living with Insulin: The Daily Reality of Dosing, Diet, and Decisions

For the person living on insulin, the therapy is an unending act of biological translation. Every meal requires an estimation of carbohydrate content, an evaluation of current blood glucose level, consideration of impending activity, and a calculation of the correct dose. A simple sandwich can become a complex algorithm factoring in the speed of carbohydrate absorption from the bread versus the fat-induced delay from the cheese. Exercise presents a labyrinth of variables—aerobic activity lowering glucose, adrenaline from anaerobic sprints spiking it, and a high risk of delayed, nocturnal hypoglycemia. Carbohydrate counting and advanced education programs like DAFNE (Dose Adjustment For Normal Eating) empower individuals to match insulin to desired food intake rather than the reverse, liberating them from rigid meal plans. However, this liberation demands constant vigilance: the threat of hypoglycemia lurks behind every miscalculation, a sudden drop that can cloud consciousness, causing shakiness, confusion, and in severe cases, seizure or coma. The condition requires an exhausting, permanent alertness that no healthy person ever experiences.

Complications: The Long-Term Consequences of Imperfect Control

Insulin is the reason people survive diabetes; managing it well is the reason they thrive. Before the era of intensive insulin therapy, the grim, late-stage complications were almost universally expected. The landmark Diabetes Control and Complications Trial (DCCT), completed in 1993, proved definitively that intensive insulin management aiming for near-normal blood glucose levels could slash the risk of microvascular complications. Tight control reduced the development of diabetic retinopathy by 76%, nephropathy by 50%, and neuropathy by 60%. This trial, and its follow-up EDIC study, forever cemented the standard of care: meticulous, multi-injection or pump therapy to drive A1C as close to normal as safely possible.

Despite these advances, diabetes remains the leading cause of new blindness in working-age adults, end-stage renal disease, and non-traumatic lower-limb amputation in many countries. Atherosclerotic cardiovascular disease is accelerated, and the combination of hypertension, dyslipidemia, and hyperglycemia makes comprehensive cardiometabolic care essential. The legacy effect, or metabolic memory, means that early, excellent glucose control protects organs for decades, while periods of chronic hyperglycemia set pathological wheels in motion that are difficult to fully stop. This is why early, intensive insulin initiation is crucial, especially in youth.

The Psychological Weight: Burnout, Burden, and Resilience

Beyond the biochemistry lies a profound psychological landscape. The constant numerical self-surveillance required to manage insulin breeds a unique form of exhaustion known as diabetes distress. It is distinct from clinical depression, though it often intertwines with it; it is the weariness of never having a day off, of feeling judged for every high glucose value, of having one’s self-worth tied inextricably to a number on a screen. Fear of hypoglycemia can become phobic, leading to deliberate under-dosing and chronic high blood sugar as a maladaptive safety behavior. Diabulimia, a dangerous eating disorder in which individuals with Type 1 diabetes skip insulin injections to lose weight through glucose excretion, is a particularly lethal manifestation of this psychological strain. Peer support, mental health integration into diabetes clinics, and cognitive behavioral therapy are now recognized as non-negotiable components of holistic care, acknowledging that a healthy pancreas does not require mental effort, and the replacement of that organ’s function places a unique tax on the human spirit.

The Frontiers of Research: Smart Insulins and Cellular Cures

The quest that began in a cluttered Toronto lab in 1921 continues on frontiers that Banting and Best could never have imagined. The ultimate goal is an insulin that works precisely when needed, without the risk of hypoglycemia. Glucose-responsive or “smart” insulin is under active investigation. These are engineered insulins that exist in an inactive, depot form in the body and activate only when glucose concentrations rise above a certain threshold, self-regulating their own bio-availability. A successful smart insulin would effectively convert a complex open-loop system into a one-shot, self-correcting closed loop, eliminating the constant external decision-making that burdens patients today. Early human trials are underway, with promising results from polymer-based and phenylboronic acid-derivative systems.

In parallel, the field of beta-cell replacement continues to advance. Islet cell transplantation from donor pancreases, pioneered through the Edmonton Protocol, has shown that insulin independence can be restored, but it is limited by donor scarcity and the need for lifelong immunosuppression. The real revolution lies in stem-cell derived therapies. Companies like ViaCyte, Vertex, and others are conducting clinical trials in which pancreatic progenitor cells derived from human pluripotent stem cells are implanted in semi-permeable encapsulation devices, maturing into functional beta cells. Early results have demonstrated robust C-peptide production and dramatic reductions in exogenous insulin requirements. The next step is engineering cells that can evade the autoimmune attack without toxic drugs, using gene-editing to create a “stealth” cell line. A true biological cure—a supply of self-renewing, protected, insulin-secreting cells—is arguably within reach for the first time.

Global Access and the Unfinished Revolution

While the technology in advanced economies races toward closed-loop perfection, a catastrophic inequity defines insulin on a global scale. One hundred years after its patent was sold for a dollar to ensure widespread access, millions of people with Type 1 diabetes in low- and middle-income countries die within a year of diagnosis due to a complete lack of affordable insulin. The World Health Organization has initiated prequalification programs for biosimilar insulins to introduce competition and drive down prices, but the market remains dominated by three multinational manufacturers. In some nations in sub-Saharan Africa and South Asia, a child with new-onset diabetes faces a life expectancy shorter than that of the dogs Banting treated in 1921. The moral wrench of having a lifesaving, mass-producible medicine that remains out of reach for economic reasons is perhaps the deepest wound of the story. Organizations like Life for a Child and the International Diabetes Federation are working to bridge this gap, supplying insulin, meters, and education to children and young adults in peril. The history of insulin is not finished until the word “manageable” applies equally to everyone, regardless of geography.

The Legacy of a Hundred-Year-Old Miracle

The discovery of insulin stands as a singular moment in human civilization. It rewired what it means to be a patient with a chronic disease. Before 1922, to be diagnosed with Type 1 diabetes was to be handed an immediate, short-term death sentence. Today, a child diagnosed with the same condition can expect to live a full, productive, and adventurous life, scaling mountains, building companies, and raising families. That is the alchemy of Banting’s late-night note, Collip’s precision, and the unglamorous heroism of countless people who use the drug daily.

Insulin is not a cure. It is a bridge—a magnificent, sturdy, but demanding bridge—between a fatal pathology and a normalized lifespan. The burden it places on the individual is immense, a 24/7 cognitive and physiological occupation. Yet the trajectory is one of relentless improvement. As smart insulins edge toward reality and stem-cell therapies graduate from promise to practice, the next century will be defined not just by management, but by restoration and protection. The spirit of Toronto in 1921—the refusal to accept that a destroyed pancreas means a destroyed life—remains the animating force of the field. The story of insulin is, at its core, a story of stubborn, ingenious hope made into a clear liquid in a sterile vial, ready to transform sugar from poison into fuel one more day.